Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.
We described and compared breast and ovarian screening practices in the 2-year period following test result disclosure in female non-carriers from BRCA1/2 mutation-positive families living in two countries, France and Quebec, Canada, which provide universal health care. Four hundred and two (France n=293; Quebec n=109) unaffected female non-carriers from BRCA-proven mutation families provided information about the uptake of mammography, clinical breast examination, breast self-examination, and ovarian ultrasounds using self-administered questionnaires. The frequency of screening practices between study cohorts were compared using logistic regression. Annual mammography was conducted in 23 and 43% of French and Quebecer women participants <50 years of age, respectively (adjusted odds ratio (aOR)=2.72; 95% confidence interval (CI), 1.08-6.81). In women ≥ 50 years of age, mammography was conducted in 49 and 65% of French and Quebecer participants (aOR=1.77; 95% CI, 0.07-4.51). Overall, 33% of French women and 39% of Quebecer women underwent at least one ovarian ultrasound during the 2-year period following BRCA1/2 test result with no significant difference between cohorts of women < 50 years of age. Among older women, Quebecers reported more frequently than French women that they had undergone ultrasound once (aOR=3.00; 95% CI, 1.02-8.83). The frequency of cancer screening practices for female non-carriers from BRCA1/2 mutation-positive families in both France and Quebec exceeded those recommended for similarly aged women in the general population. Our findings highlight the need for clearcut recommendations on the follow-up of women from BRCA1/2 families who are not themselves carriers of a BRCA1/2 mutation.
Faculté de Pharmacie, Université Laval, Québec, QC, Canada. mdorval@uresp.ulaval.ca
Michel
M
Dorval
Catherine
C
Noguès
Pascaline
P
Berthet
Jocelyne
J
Chiquette
Marion
M
Gauthier-Villars
Christine
C
Lasset
Claude
C
Picard
Marie
M
Plante
Jacques
J
Simard
Claire
C
Julian-Reynier
D000328:Adult; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D015331:Cohort Studies; D055088:Early Detection of Cancer / Q000706:statistics & numerical data*; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D005602:France; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D011792:Quebec
Breast Cancer Res Treat. 2011 Jan;125(1):169-73
20458532
Breast Cancer Res Treat. 2010 Jan;119(2):409-14
19885732
J Clin Oncol. 2008 Jan 10;26(2):225-32
18040054
N Engl J Med. 1998 Apr 16;338(16):1089-96
9545356
J Obstet Gynaecol Can. 2007 Jan;29(1):45-60
17346477
Br J Cancer. 2007 Mar 12;96(5):718-24
17285126
J Public Health Med. 1998 Dec;20(4):396-403
9923945
J Med Genet. 2007 Feb;44(2):107-21
16905680
Lancet Oncol. 2007 Dec;8(12):1042-1043
18054868
Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1182-7
14652278
Br J Cancer. 2005 Sep 5;93(5):590-6
16136033
J Clin Oncol. 2006 Jul 20;24(21):3361-6
16801631
Bull Cancer. 2004 Mar;91(3):219-37
15171047
Radiat Res. 2002 Aug;158(2):220-35
12105993
JAMA. 1995 Feb 8;273(6):491-7
7837369
J Gynecol Obstet Biol Reprod (Paris). 2006 Jun;35(4):373-87
16940906
Eur J Hum Genet. 1997;5 Suppl 1:1-90
9101171
Ann Intern Med. 1991 Apr 15;114(8):657-61
2003712
Am J Public Health. 1990 Nov;80(11):1386-8
2240315
N Engl J Med. 2008 Jun 26;358(26):2796-803
18579814
Bull Cancer. 1999 Mar;86(3):307-13
10210766
J Genet Couns. 2007 Jun;16(3):241-60
17508274
Am J Public Health. 1992 Feb;82(2):249-51
1739156
J Genet Couns. 2008 Aug;17(4):314-26
18481164